Prespecified secondary analysis of AZALEA-TIMI 71 in atrial fibrillation: prior oral anticoagulant use indicated bleeding risk; factor XI inhibitor abelacimab reduced bleeding regardless, with potentially greater absolute benefit in OAC-naive patients.
Secondary analysis
Small et al. Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study